The effects of medical management on the progression of diabetic retinopathy in persons with type 2 diabetes: the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Eye Study
- PMID: 25172198
- PMCID: PMC4252767
- DOI: 10.1016/j.ophtha.2014.07.019
The effects of medical management on the progression of diabetic retinopathy in persons with type 2 diabetes: the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Eye Study
Abstract
Purpose: To report additional ocular outcomes of intensive treatment of hyperglycemia, blood pressure, and dyslipidemia in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) study.
Design: Double 2×2 factorial, multicenter, randomized clinical trials in people with type 2 diabetes who had cardiovascular disease or cardiovascular risk factors. In the glycemia trial, targets of intensive and standard treatment were: hemoglobin A1c <6.0% and 7.0% to 7.9%, respectively, and in the blood pressure trial: systolic blood pressures of <120 and <140 mmHg, respectively. The dyslipidemia trial compared fenofibrate plus simvastatin with placebo plus simvastatin.
Participants: Of the 3472 ACCORD Eye Study participants enrolled, 2856 had 4-year data (85% of survivors).
Methods: Eye examinations and fundus photographs were taken at baseline and year 4. Photographs were graded centrally for retinopathy severity and macular edema using the Early Treatment Diabetic Retinopathy Study (ETDRS) methods.
Main outcome measures: Three or more steps of progression on the ETDRS person scale or treatment of retinopathy with photocoagulation or vitrectomy.
Results: As previously reported, there were significant reductions in the primary outcome in the glycemia and dyslipidemia trials, but no significant effect in the blood pressure trial. Results were similar for retinopathy progression by 1, 2, and 4 or more steps on the person scale and for ≥ 2 steps on the eye scale. In the subgroup of patients with mild retinopathy at baseline, effect estimates were large (odds ratios, ∼0.30; P < 0.001), but did not reach nominal significance for participants with no retinopathy or for those with moderate to severe retinopathy at baseline.
Conclusions: Slowing of progression of retinopathy by intensive treatment of glycemia was observed in ACCORD participants, whose average age and diabetes duration were 62 and 10 years, respectively, and who had cardiovascular disease or cardiovascular risk factors. The effect seemed stronger in patients with mild retinopathy. Similar slowing of progression was observed in patients treated with fenofibrate, with no effect observed with intensive blood pressure treatment. This is the second study to confirm the benefits of fenofibrate in reducing diabetic retinopathy progression, and fenofibrate should be considered for treatment of diabetic retinopathy.
Trial registration: ClinicalTrials.gov NCT00000620 NCT00542178.
Copyright © 2014 American Academy of Ophthalmology. Published by Elsevier Inc. All rights reserved.
Conflict of interest statement
There are no conflicts of interest from the other authors.
Figures
![Figure 1](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/4252767/bin/nihms616809f1.gif)
Comment in
-
Systemic therapies for diabetic retinopathy: the accord eye study.Ophthalmology. 2014 Dec;121(12):2295-6. doi: 10.1016/j.ophtha.2014.08.019. Epub 2014 Nov 24. Ophthalmology. 2014. PMID: 25459462 No abstract available.
Similar articles
-
Persistent Effects of Intensive Glycemic Control on Retinopathy in Type 2 Diabetes in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Follow-On Study.Diabetes Care. 2016 Jul;39(7):1089-100. doi: 10.2337/dc16-0024. Epub 2016 Jun 11. Diabetes Care. 2016. PMID: 27289122 Free PMC article. Clinical Trial.
-
Effects of medical therapies on retinopathy progression in type 2 diabetes.N Engl J Med. 2010 Jul 15;363(3):233-44. doi: 10.1056/NEJMoa1001288. Epub 2010 Jun 29. N Engl J Med. 2010. PMID: 20587587 Free PMC article. Clinical Trial.
-
Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial.Lancet. 2007 Nov 17;370(9600):1687-97. doi: 10.1016/S0140-6736(07)61607-9. Epub 2007 Nov 7. Lancet. 2007. PMID: 17988728 Clinical Trial.
-
Fenofibrate for diabetic retinopathy.Cochrane Database Syst Rev. 2023 Jun 13;6(6):CD013318. doi: 10.1002/14651858.CD013318.pub2. Cochrane Database Syst Rev. 2023. PMID: 37310870 Free PMC article. Review.
-
Fenofibrate - a potential systemic treatment for diabetic retinopathy?Am J Ophthalmol. 2012 Jul;154(1):6-12. doi: 10.1016/j.ajo.2012.03.013. Am J Ophthalmol. 2012. PMID: 22709833 Review.
Cited by
-
Comparison of diabetic retinopathy screening between hospital-based multidisciplinary and general practice-based settings: insights from a regional study in Italy.Acta Diabetol. 2024 Aug 19. doi: 10.1007/s00592-024-02354-6. Online ahead of print. Acta Diabetol. 2024. PMID: 39160371
-
Design and Assessment of First-Generation Heterobifunctional PPARα/STING Modulators.ACS Med Chem Lett. 2024 Jul 22;15(8):1279-1286. doi: 10.1021/acsmedchemlett.4c00153. eCollection 2024 Aug 8. ACS Med Chem Lett. 2024. PMID: 39140058
-
Short-Term Clinical Outcomes of Patients with Diabetic Macular Edema Following a Therapy Switch to Faricimab.J Clin Med. 2024 Aug 1;13(15):4508. doi: 10.3390/jcm13154508. J Clin Med. 2024. PMID: 39124774 Free PMC article.
-
Role of Systemic Factors in Improving the Prognosis of Diabetic Retinal Disease and Predicting Response to Diabetic Retinopathy Treatment.Ophthalmol Sci. 2024 Feb 17;4(4):100494. doi: 10.1016/j.xops.2024.100494. eCollection 2024 Jul-Aug. Ophthalmol Sci. 2024. PMID: 38694495 Free PMC article. Review.
-
The Association of Sickle-Cell Disorders With Diabetic Retinopathy: A Large Database Study.Ophthalmol Sci. 2024 Feb 13;4(4):100490. doi: 10.1016/j.xops.2024.100490. eCollection 2024 Jul-Aug. Ophthalmol Sci. 2024. PMID: 38694493 Free PMC article.
References
-
- The ACCORD Study Group. Action to Control Cardiovascular Risk in Diabetes (ACCORD) Trial: design and methods. Am J Cardiol. 2007;99(Suppl):21i–33i. - PubMed
Publication types
MeSH terms
Substances
Associated data
Grants and funding
- N01HC95183/HC/NHLBI NIH HHS/United States
- ZIA EY000410-08/ImNIH/Intramural NIH HHS/United States
- Y01 HC001010/HC/NHLBI NIH HHS/United States
- N01HC95178/HC/NHLBI NIH HHS/United States
- N01-HC-95180/HC/NHLBI NIH HHS/United States
- IAAY1-HC-9035/HC/NHLBI NIH HHS/United States
- N01-HC-95184/HC/NHLBI NIH HHS/United States
- IAA-Y1-HC-1010/HC/NHLBI NIH HHS/United States
- N01-HC-95183/HC/NHLBI NIH HHS/United States
- N01-HC-95178/HC/NHLBI NIH HHS/United States
- N01HC95182/HC/NHLBI NIH HHS/United States
- N01-HC-95179/HC/NHLBI NIH HHS/United States
- N01-HC-95181/HC/NHLBI NIH HHS/United States
- N01HC95179/HC/NHLBI NIH HHS/United States
- N01HC95180/HC/NHLBI NIH HHS/United States
- N01HC95181/HC/NHLBI NIH HHS/United States
- N01HC95184/HC/NHLBI NIH HHS/United States
- N01-HC-95182/HC/NHLBI NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials